KRTL Holding Group Provides KRTL Biotech Update on

New Post Public Reply Private Reply Replies (0) Message Board
louied91
80
KRTL Holding Group Provides KRTL Biotech Update on Pharmaceutical, Botanical and Federal Development

https://www.otcmarkets.com/stock/KRTL/news/KR...?id=535888  

KRTL Holding Group Inc. (OTC: KRTL) (“KRTL” or the “Company”) today provided shareholders with an update on KRTL Biotech Inc., the Company’s wholly owned life-sciences subsidiary, and the pharmaceutical, botanical, regulatory and federal capabilities being developed within the business.

The update is the second in KRTL’s shareholder series. KRTL Biotech has spent the past year assembling a more defined platform around pharmaceutical and API development, botanical extracts, regulatory qualification, strategic partnerships and commercialization.

KRTL Holding Group management stated: “KRTL Biotech has progressed from identifying opportunities to building the regulatory, technical and commercial framework needed to evaluate and advance them. Rayel and Periko, our pharmaceutical and API strategy, expanded regulatory leadership and federal registrations are increasingly becoming connected parts of one life-sciences platform.”

KRTL Biotech Within the KRTL Organization

KRTL Biotech Inc. is a wholly owned subsidiary of KRTL Holding Group Inc. and serves as the Group’s life-sciences, pharmaceutical, botanical and regulatory-development platform. The Knowledge Research and Technology Labs Corp., DBA The K.R.T.L., operates beneath KRTL Biotech within the current corporate structure.

Rayel and Periko — Parallel Botanical, Commercial and Pharmaceutical Development

A central component of KRTL Biotech’s strategy is Rayel and Periko, two separate coca-derived formula and extract platforms that management views as distinct and equally important assets.

KRTL is pursuing multiple pathways around both platforms, including non-psychoactive and decocainized applications, botanical and specialty ingredients, beverage and flavor applications, analytical and research uses, formulation partnerships, pharmaceutical development, API-oriented opportunities, and regulated psychoactive or controlled-substance pathways.

Company records include a TTB formula approval record for Rayel Decocainized Natural Coca Extract, providing an existing regulatory foundation for its applicable beverage-facing use. KRTL is working to advance the commercial arrangements, manufacturing relationships and qualified partners needed to move applicable opportunities forward. Rayel and Periko may also be developed or licensed independently, together, by territory or by field of use.
Developing a South American API-to-U.S. Supply Strategy

KRTL Biotech is evaluating opportunities to develop pharmaceutical APIs and related supply relationships in South America for potential importation into the United States and participation in the U.S. pharmaceutical supply chain.

As part of that strategy, KRTL is working with prospective partners toward the development of an API manufacturing facility in South America capable of producing selected pharmaceutical APIs. The contemplated model is partner-led, bringing together qualified manufacturing, technical, quality and regulatory participants.

The objective is to connect API identification and development with qualified manufacturing, analytical validation, regulatory documentation, importation and downstream U.S. pharmaceutical relationships. KRTL’s qualification framework includes review of quality systems, API and CMC documentation, analytical specifications, facility and supplier qualification, traceability, import pathways and, where applicable, controlled-substance registration, security, quota and import/export requirements.
Expanding Regulatory Leadership

KRTL Biotech has strengthened its regulatory capabilities through the addition of Justin Abril as President-Designate and Strategic Regulatory & API Consultant.

Abril brings more than a decade of experience involving federal controlled-substance compliance, Schedule I manufacturing, DEA regulatory affairs, pharmaceutical quality systems and regulated supply chains. His role is intended to help KRTL evaluate prospective manufacturers, laboratories, APIs, botanical sources and pharmaceutical opportunities against the technical, quality and regulatory requirements necessary for advancement.

KRTL Holding Group management stated: “Identifying an opportunity is only the beginning. The next question is whether the facility, supplier, compound or manufacturing pathway can meet the regulatory, quality, analytical, security and documentation requirements necessary to move forward. Strengthening that capability allows us to evaluate opportunities more systematically.”
Expanding University and Research Collaboration

KRTL Biotech is also expanding its research-development efforts around coca-derived compounds and related botanical and pharmaceutical pathways. The company has begun outreach to universities and research institutions regarding potential research collaborations, with introductory calls currently scheduled.

These discussions are intended to explore areas such as analytical research, compound characterization, botanical science, pharmaceutical development and other research programs that may support the broader Rayel, Periko and coca-development strategy.
Building Federal and Regulatory Infrastructure

KRTL Biotech maintains an active SAM.gov registration with UEI ULPJWZWBM9L5, CAGE/NCAGE 109P9 and Purpose of Registration: All Awards. KRTL Biotech also maintains federal registrations and entity identifiers with the U.S. Food and Drug Administration and SAM.gov.

Management views this infrastructure as supporting potential engagement with federal agencies, research organizations, prime contractors and other government-market participants, as well as the company’s ability to evaluate qualifying federal contracting, research and assistance opportunities. These registrations provide federal identity and visibility; they do not themselves constitute a government contract, funding award, FDA approval of a particular product or DEA authority for a controlled-substance activity.
Strengthening Regulatory, Qualification and Consulting Services

As KRTL Biotech builds regulatory and qualification systems around its own pharmaceutical and botanical programs, the company is also developing processes involving supplier and facility qualification, pharmaceutical quality systems, registration readiness, controlled-substance compliance planning, import/export pathway analysis, documentation, security requirements and inspection readiness.

Those capabilities are intended first to support KRTL’s own programs but may also create future opportunities to provide advisory, readiness and qualification services to appropriately situated third parties facing similar regulatory and supply-chain challenges. Management believes this strengthens KRTL Biotech’s consulting services by applying the same regulatory, quality, security and supply-chain disciplines being developed for internal programs to qualified outside engagements.
What These Developments Mean Together

Management believes the significance of KRTL Biotech becomes clearer when these developments are viewed together. Rayel and Periko provide two distinct coca-derived platforms being advanced across non-psychoactive, decocainized, commercial, pharmaceutical, API-oriented and regulated psychoactive pathways. The South American API strategy connects opportunity identification with partner-led manufacturing, qualification and potential U.S. importation. Expanded regulatory leadership strengthens KRTL’s ability to evaluate those opportunities, university and research-institution outreach adds a developing research pathway, and federal registrations and consulting capabilities broaden the platform’s institutional and service capabilities.

Together, these efforts are intended to develop KRTL Biotech into a broader pharmaceutical, botanical, regulatory and commercialization platform capable of identifying opportunities, qualifying partners, structuring development pathways and participating in supply-chain and commercial relationships.
What Comes Next

KRTL Biotech’s next phase is focused on advancing Rayel and Periko commercial and pharmaceutical development, pursuing qualified partners for the South American API manufacturing strategy, evaluating API opportunities for potential U.S. importation, advancing scheduled discussions with universities and research institutions regarding coca-related research collaboration, expanding pharmaceutical relationships, strengthening regulatory and consulting capabilities and identifying opportunities connected to the company’s federal infrastructure.

KRTL Holding Group management stated: “We believe the individual pieces are increasingly coming together. Our focus now is on converting platform assets, regulatory work, technical relationships and federal infrastructure into defined commercial, pharmaceutical and strategic programs.”
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 163

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 171

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 130

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 221

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 166

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 192

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading

Top 5 Most Recently Viewed Articles

Síminn hf. Achieves Strong Growth in Q2 2025 Results

Updated Category News Views 303

Exciting Financial Highlights from Síminn hf. for Q2 2025 In the second quarter of 2025, Síminn hf. reported remarkable financial growth, demonstrating their resilient operations and commitment to enhancing customer value. The total revenue surged to ISK 7,196 million, marking a 4.7% increase compared to Q2 2024, where revenues stood at ISK 6,871 million. This positive...

Continue Reading
Pacesetter Joins Inc.'s 2026 Best Workplaces List

Updated Category News Views 33

Pacesetter Technology Earns a Spot on Inc.'s Renowned List How many times have we heard companies rattle on about employee satisfaction and culture? But this time, we're talking about a company, Pacesetter Technology, that didn't just talk the talk—they walked right into Inc.'s 2026 Best Workplaces spotlight. And in an era where employers hold all the cards, that's no...

Continue Reading
Discover Meiyume's Innovative Beauty Solutions at Cosmopack

Updated Category News Views 272

Unveiling Meiyume at Cosmopack Asia 2025 Hong Kong, leading the way in beauty solutions, is set to host an influential event as Meiyume showcases its innovative initiative titled SEEDED — Rooted in Intelligence, Connected Through the Beauty Vein at Cosmopack Asia. With a strong foothold in packaging and product development, Meiyume leverages its proprietary Beauty...

Continue Reading
MAHA Action, Inc. Announces Support for Zach Lahn's Governor Bid

Updated Category News Views 215

MAHA Action, Inc. Endorses Zach Lahn for Iowa Governor MAHA™ Action, Inc., a prominent advocate for health freedom, proudly announces its endorsement of Zach Lahn as the next Governor of Iowa. Lahn has launched an Iowa First platform aimed at empowering residents and improving personal liberties. Commitment to Health Freedom Lahn has emerged as a vigorous champion of...

Continue Reading
Couchbase Reports Impressive Q1 Earnings Amid Rising Demand

Updated Category News Views 309

Financial Performance Highlights for Couchbase Couchbase, Inc. (NASDAQ: BASE), the leading developer data platform that powers critical applications in today’s AI-driven world, has unveiled its financial performance for the first quarter ended April 30, 2025. With a remarkable increase in revenue and strong annual recurring revenue (ARR), Couchbase has demonstrated the...

Continue Reading